Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UQEBM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2024181570A1 ADC10
|
|||||
| Synonyms |
WO2024181570A1 ADC10
Click to Show/Hide
|
|||||
| Organization |
TAIHO PHARMACEUTICAL CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Antibody 5
|
Antibody Info | ||||
| Antigen Name |
Syndecan-1 (SDC1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
ADC-specific functional property(2027 Update)
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 29 ng/mL | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3674 ng/mL | Negative CD138 expression (CD138-) | ||
| Method Description |
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||